BioMarin Pharmaceutical/ US09061G1013 /
| 2024-04-19 7:35:03 PM | Chg. -1.47 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 88.61USD | -1.63% | 92,027 Turnover: 8.2 mill. |
-Bid Size: - | -Ask Size: - | 16.76 bill.USD | - | 99.84 |
Assets
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 798.7680 | 896.7000 | 948.6820 | 1,010.8680 | 1,032.4710 | ||||||
| Intangible Assets | 553.7800 | 517.5100 | 491.8080 | 456.5800 | 417.2710 | ||||||
| Long-Term Investments | 572.7110 | 385.7850 | 235.8640 | 411.9780 | 285.4730 | ||||||
| Fixed Assets | 2,601.8990 | 2,425.9810 | 2,370.9130 | 2,747.8960 | 3,505.8010 | ||||||
| Inventories | 355.1260 | 475.7750 | 530.8710 | 680.2750 | 698.5480 | ||||||
| Accounts Receivable | 215.2800 | 261.3650 | 342.6330 | 377.4040 | 448.3510 | ||||||
| Cash and Cash Equivalents | 408.3300 | 598.0280 | 493.9820 | 437.4460 | 649.1580 | ||||||
| Current Assets | 1,421.7910 | 2,207.1440 | 2,056.2150 | 1,942.1430 | 2,342.2190 | ||||||
| Total Assets | 4,023.6900 | 4,633.1250 | 4,427.1280 | 4,690.0390 | 5,848.0200 | ||||||
Liabilities
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | 660.7610 | 813.5210 | 830.4170 | 486.2380 | 1,075.1450 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,257.4150 | 1,824.4620 | 1,459.1880 | 1,567.6580 | 1,742.0180 | ||||||
| Share Capital | .1730 | .1760 | .1780 | .1800 | .1820 | ||||||
| Total Equity | 2,766.2750 | 2,808.6630 | 2,967.9400 | 3,122.3810 | 4,106.0020 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 4,023.6900 | 4,633.1250 | 4,427.1280 | 4,690.0390 | 5,848.0200 | ||||||
Income Statement
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,116.8540 | 1,313.6460 | 1,491.2120 | 1,704.0480 | 1,860.4550 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -803.4290 | -14.7000 | -123.5240 | -100.4570 | -36.7650 | ||||||
| Interest Income | -32.0120 | -27.8540 | -20.8330 | -.7120 | -12.6990 | ||||||
| Income Before Taxes | -831.0500 | -35.8750 | -142.7050 | -94.8110 | -42.3220 | ||||||
| Income Taxes | -200.8400 | 81.1670 | -65.4940 | -70.9630 | -901.4220 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -630.2100 | -117.0420 | -77.2110 | -23.8480 | 859.1000 | ||||||
Per Share
Cash Flow
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -227.8370 | -8.7570 | 20.2080 | 48.2620 | 85.3650 | ||||||
| Cash Flow from Investing Activities | -484.0470 | -305.4590 | 264.3510 | -31.0260 | -53.6210 | ||||||
| Cash Flow from Financing | 727.1080 | 507.1450 | -388.0070 | -74.6740 | 181.1180 | ||||||
| Decrease / Increase in Cash | 11.2900 | 189.6980 | -104.0460 | -56.5360 | 211.7120 | ||||||
| Employees | 2,293 | 2,581 | 2,849 | 3,001 | 3,059 | ||||||
